According to the Associated Press, the FDA will add its strongest warning yet to MRI imaging drugs that contain the chemical gadolinium. The label will warn about the danger the imaging agents can pose to patients with kidney problems.
READ MORE MRI HEALTH RISK LEGAL NEWS
Specifically, three types of gadolinium-based contrast agents - Magnevist, Omniscan and Optimark - will be "described as inappropriate for use among patients with acute kidney injury or chronic severe kidney disease," according to the FDA.
Dr. Rafel Rieves, director of the Division of Medical Imaging Products in the FDA's Center for Drug Evaluation and Research said that the warnings are being added to enhance patient safety.
"The FDA is requiring these labeling changes to enhance the safe use of gadolinium-based contrast agents, including avoidance of certain agents among patients at highest risk for nephrogenic systemic fibrosis," he said.